Betamethasone:9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
|
Anticholinesterases May antagonize anticholinesterase effects in myasthenia gravis.
Anticoagulants, oral May alter anticoagulant dose requirements.
Barbiturates May decrease pharmacologic effect of betamethasone.
Hydantoins, rifampin May increase Cl and decrease therapeutic efficacy of betamethasone.
Nondepolarizing muscle relaxants (eg, tubocurarine) May potentiate or counteract neuromuscular blocking action.
Salicylates May reduce serum levels and efficacy of salicylates.
Troleandomycin May increase effects of betamethasone.
|